Answers are grounded in this paper and cite their sources.
In recent years, immune checkpoint inhibitors (ICIs) have become an important treatment strategy for advanced gastric cancer. Immunotherapy has gradually transitioned from a later-line to a first-line treatment for advanced gastric cancer. Simultaneously, more and more researchers have begun to pay attention to whether immunotherapy can be used for resectable gastric cancer. The current use of ICIs in the neoadjuvant treatment of gastric cancer is still in its exploratory stage, with a number of clinical trials currently underway. However, the available data show good application prospects. This article reviews the research progress on ICIs in the neoadjuvant therapy for gastric cancer and evokes some unresolved problems.
No takes yet. Share an insight, caveat, or question.
Li et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: